To compare the efficacy and toxicity of the same or similar total daily doses of aminoglycosides administered by either conventional (multiple daily dosing) or extended-interval dosing methods.
Results of the review
Twnty-two RCTs with a total of 2,500 patients were included.
The results of treatment failure were statistically significantly heterogeneous across studies (p=0.005). Extendedinterval dosing was associated with a statistically significant reduction in risk of treatment failure (risk difference -3.4%; 95% CI: -6.7%, -0.2%; p=0.04). Reclassification of intermediate outcomes as failure yielded a smaller risk difference (risk difference -3.1%; 95% CI: -7.4%, 1.1%; p=0.15).
There was a trend toward reduced risk of bacteriologic failure in the extended-interval dosing group (risk difference -1.7%; 95% CI: -5.4%, 2.1%; p=0.38).
There was no significant difference between extended-interval dosing and conventional dosing in nephrotoxicity (risk difference-0.6%; 95% CI: -2.4%, 1.1%; p+0.46) and in ototoxicity (risk difference 0.3%; 95% CI: -1.2%, 1.8%; p=0.71).
Authors' conclusions
For many indications, extended-interval dosing of aminoglycosides appears to be as effective as conventional dosing, with similar rates of toxicity. The added convenience of extended-interval dosing makes it an attractive alternative to conventional dosing.
CRD commentary
The search strategy, inclusion criteria and quality assessment were satisfactorily reported. The patients' characteristics
